Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Cuts Q2 Loss on Lower Spending

NEW YORK (GenomeWeb News) – Med BioGene late Friday reported that it cut its second-quarter net loss 17 percent due to a decreased R&D spending.
 
The Vancouver, British Columbia-based molecular diagnostics firm reported no revenues for the quarter.
 
Its net loss dropped to $616,733, or $.02 per share, compared to a loss of $741,421, or $.03 per share, for the second quarter of 2007. “The decrease was a result of reduced stock-based compensation expenses and reduced laboratory supply expenses partially offset by increased business development costs as MBI continues to develop and execute upon its commercialization strategy,” the firm said in a statement.
 
MBI’s R&D expenses fell to $261,101 from $399,867 year over year, while its general and administrative costs inched up to $336,207 from $326,020 in the second quarter of 2007.
 
The firm is gearing up for the launch of LungExpress Dx, a gene expression-based prognostic test for lung cancer, which it hopes to market in 2009.
 
MBI finished the quarter with $397,079 in cash and cash equivalents.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.